Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Aldeyra Therapeutics nets $11.2mm in IPO

Executive Summary

Aldeyra Therapeutics Inc., working on drug candidates that trap and help dispose of free aldehydes, netted $11.2mm in its initial public offering of 1.5mm shares at $8. When the company initially filed in January, it was known as Aldexa Therapeutics, but changed its name to Aldeyra in March, the same time it proposed selling 2mm shares between $10-12 each, then a few days later upped the number of shares to 2.3mm.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • IPO

Related Companies